The first evidence that adrenocortical hyperplasia involves a fault in steroid metabolism was provided by with the isolation of large amounts of pregnane-3a,17a,20a-triol from three cases of adrenocortical hyperplasia. This compound was later isolated by Mason and Kepler (4) from three patients with hyperplasia and also from a patient with an adrenocortical tumor, and by Miller and Dorfman (5) from a further case of adrenal hyperplasia. More recently Cox and Marrian (6) isolated it in small quantities from the urine of normal men. The closely related compound pregnane-3a,17a,20a-triol-1 1-one was isolated from the urine of two patients with adrenocortical hyperplasia by Finkelstein, v. Euw, and Reichstein (7) and more recently by Fukushima, Meyer, Ashworth, and Gallagher (8). The demonstration of the effectiveness of cortisone administration in the relief of symptoms of adrenocortical hyperplasia by Wilkins, Lewis, Klein, and Rosemberg (9) stimulated research into steroid metabolism in this condition.
The first evidence that adrenocortical hyperplasia involves a fault in steroid metabolism was provided by with the isolation of large amounts of pregnane-3a,17a,20a-triol from three cases of adrenocortical hyperplasia. This compound was later isolated by Mason and Kepler (4) from three patients with hyperplasia and also from a patient with an adrenocortical tumor, and by Miller and Dorfman (5) from a further case of adrenal hyperplasia. More recently Cox and Marrian (6) isolated it in small quantities from the urine of normal men. The closely related compound pregnane-3a,17a,20a-triol-1 1-one was isolated from the urine of two patients with adrenocortical hyperplasia by Finkelstein, v. Euw, and Reichstein (7) and more recently by Fukushima, Meyer, Ashworth, and Gallagher (8) . The demonstration of the effectiveness of cortisone administration in the relief of symptoms of adrenocortical hyperplasia by Wilkins, Lewis, Klein, and Rosemberg (9) stimulated research into steroid metabolism in this condition.
A method for the quantitative estimation of pregnane-3a,17a,20a-triol and other 17,20-dihydroxy-20 methyl steroids ("acetaldehydogenic steroids") was developed by Cox (10) . The acid and enzymic hydrolysis of conjugates of these steroids and their chromatographic separation were investigated by Cox and Marrian (11, 6) . Bongiovanni, Clayton, and Eberlein (12, 13) , using a reaction based on chromogen production with sulfuric acid, have estimated the excretion of a pregnanetriol-like fraction in adrenocortical hyperplasia, and Zondek and Finkelstein (14, 15) like fraction to distinguish congenital adrenocortical hyperplasia from true hermaphroditism and male pseudo-hermaphroditism. None of these methods is specific for any single compound.
More recently Finkelstein and Goldberg (16, 17) developed an analytical method including paper chromatographic separation for the estimation of pregnane-3a,17a,20a-triol-11-one in human urine. They reported the presence of this compound in the urines of patients with adrenocortical hyperplasia, but not in detectable amounts in the urine of normal people or of patients with adrenal tumors. Because of this finding the latter workers suggested that the presence of pregnanetriolone is characteristic of adrenal hyperplasia and that its detection may be useful in the diagnosis of this condition. By contrast, since pregnanetriol appears to be excreted in greater than normal amounts by patients with tumors of adrenal origin as well as by patients with adrenal hyperplasia, its excretion at abnormally high levels cannot be considered characteristic of adrenal hyperplasia. However, the estimation of pregnanetriolone and pregnanetriol simultaneously is of obvious value in the diagnosis and differentiation of adrenal hyperplasia and adrenal tumors.
A procedure for the simultaneous estimation of pregnanetriol and pregnanetriolone was briefly described by Finkelstein and Cox (18) . The present paper describes in detail a method for the identification and estimation of both pregnane3a,17a,20a-triol and pregnane-3a,17a,20a-triol- roform extracts are washed with 20 ml. N sodium hydroxide and the alkali is drained off as thoroughly as possible. The emulsion at the interface is discarded. The chloroform is washed with 10 ml. of 8 per cent sodium bicarbonate solution, draining off the alkali thoroughly. The chloroform extract is run into a clean funnel and washed with 10 ml. of water twice. The washed chloroform is run into a dry flask containing 2 Gm. anhydrous sodium sulfate and the flask is shaken and allowed to stand for ten minutes. The chloroform is filtered through filter-paper into a 1-liter round bottom flask for evaporation. The evaporation is carried out under reduced pressure on a water bath, making sure that the flask is removed from the bath as soon as the last drop of chloroform has evaporated. The residue is dissolved with slight warming in 3 ml. of ethanol and the ethanol extract transferred with a pipette to a graduated centrifuge tube. The flask is rinsed again twice with 1 ml. portions of ethanol. The volume is made up to 5 ml. and stirred to mix the solutions. The portions shown in Figure 1 Figure 1) ; The paper is marked in pencil on the headband with the reference number and letter as shown in Figure 1 .
For the first chromatogram the benzene-formamide system is used. Equal volumes (500 ml.) of benzene and formamide are equilibrated at 370 C., and the layers are separated in a funnel at 370 C.; these equilibrated sol- 4 We are indebted to Dr. S. E. Wright for suggesting the use of this modification of the horizontal chromatographic tank.
vents may be stored at room temperature until required for use. The stock bottles are shaken before withdrawing samples of the solvents. The chromatogram trays are warmed for at least one hour in the 37°C incubator used for chromatography before starting a run. The ground glass edge of the tray is moistened with formamide to provide a seal and 100 ml. of equilibrated benzene is run into the tray at the start of the warming period.
To impregnate the paper with formamide, 10 ml. of formamide (equilibrated with benzene at 37°C.) is freshly mixed with one volume of methanol. The paper is dipped through the mixture quickly and the excess liquid blotted off thoroughly between filter paper.
The paper is placed on a glass rack with a nitrogen distributor about 3 cm. from the paper surface. An electric lamp to provide gentle warmth and speed up evaporation of the solvent applied with the extracts is placed close to the paper. The extracts in the test tubes are dissolved by adding 0.05 ml. of methanol to each and warming slightly. Each extract is transferred to a strip on the chromatogram with a pipette and the paper is spotted along as narrow a line as possible. To the residue in the test tube is added 0.01 ml. of methanol and this wash is transferred to the paper. The wash is repeated with 0.01 ml. of methanol. To the strip with extract G is added 10 jg. of triol and 3 ;Lg .of triolone in methanol, and to the sixth strip S is added these amounts of pure substances alone. When the methanol has dried off, the chromatogram is placed on the glass rack in the prewarmed tank at 370 C. and the run is started by dipping the end of the paper in the solvent. The chromatogram is allowed to run for 2 to 3 hours when the solvent front should have travelled about 30 cm.
At the end of the run the chromatogram is removed The strips are treated with phosphoric acid after running the chromatogram. As an alternative to the ethylene dichloride-formamide system, the chloroform-formamide system may be used but in this case the chloroform should be freshly distilled as required.
The distances moved by pregnanetriol and pregnanetriolone relative to the solvent fronts are 0.3, 0.08 (benzeneformamide); 0.7, 0.4 (ethylene dichloride-formamide); 0.75, 0.5 (chloroform-formamide), respectively. These values apply to the apparatus and conditions used above and may vary somewhat, but are given as a guide (see Figure 3) .
RESULTS
Using the method described, the urinary levels of pregnanetriol and pregnanetriolone shown in Table 1 were found for 24 normal adults and children, 6 patients with adrenocortical hyperplasia before treatment, 10 patients with adrenocortical hyperplasia receiving cortisone, prednisolone or similar therapy, and a patient with a tumor of adrenal origin. The observed values for pregnanetriol and pregnanetriolone on the first and second chromatograms are given. Between the normal groups and the patients with adrenocortical hyperplasia there is a clear difference. In the latter, pregnanetriolone is excreted in relatively large amounts and there is an associated increase in the pregnanetriol levels. The absence of pregnanetriolone with tumors of adrenal origin is suggested by the case reported here and by the two cases of women, one with a virilizing adrenal tumor and the other with an adrenal adenoma, noted by Finkelstein and Goldberg (17) . Differentiation of patients with tumors of adrenal origin from adrenocortical hyperplasia on the basis of the pregnanetriolone excretion seems possible. Confirmation of this supposition awaits study of further cases, but it does not appear unreasonable in view of the very definite excretion of pregnanetriolone by every one of twelve patients with adrenocortical hyperplasia (present paper, six cases), its excretion by six hyperplasia patients maintained on cortisone or similar therapy, and its absence in the three tumor cases.
Cortisone treatment is known to decrease the pregnanetriol values (22) and pregnanetriolone values (15 plasia but on steroid therapy, the 17-ketosteroid excretion was within the normal range, whereas marked amounts of pregnanetriolone were still being excreted.
Presence of other compounds besides pregnanetriol and pregnanetriolone
In some of the chromatograms of the 41 urine extracts reported in this paper, there appeared a number of other spots of a variety of colors apart from the spots of pregnanetriol and pregnanetriolone. Most of the blue colors which have been observed were notably different from the blue-violet color given by pregnanetriolone in the color test. With high levels of pregnanetriol and pregnanetriolone, the presence of other spots did not interfere with the detection and estimation of these steroids on the first chromatogram. However, in extracts from some of the normal subjects, interference was found in the first chromatogram because of the relatively low levels or absence of the steroids. No interference was noted in the second chromatogram even if it occurred on the first.
It should be noted that the spots which are estimated as pregnanetriol and pregnanetriolone are assumed to be these compounds from the colors developed in the phosphoric acid reaction and from their RF values. However, it is possible that closely related compounds may not be distinguished, especially at low levels of pregnanetriol and pregnanetriolone. Thus, samples 162, 163, and 167 in the normal group showed faint spots corresponding to pregnanetriolone; however, the higher resolution of a 27 hour descending chromatogram showed that these trace substances were not pregnanetriolone. With all the adrenocortical hyperplasia patients, pregnanetriolone showed up very clearly; usually the spot was so intense as to require dilution of fractions for the second chromatogram. Two liters of urine from an adrenocortical hyperplasia patient, R. M., sample 166, were processed by this method except for the use of a sheet of Whatman No. 3 MM paper for chromatography. From the area on the paper corresponding to pregnanetriolone a substance was isolated directly after the second chromatogram. This substance was identified as pregnanetriolone from its infra-red absorption spectrum. The compounds recently isolated by Fukushima, Meyer, Ashworth, and Gallagher (8), allopregnane-3a, 17a,20a-triol and pregnane-3a,1 li,17a,20a-tetrol,5 are completely resolved from pregnanetriol and pregnanetriolone in the benzene-formamide system as used in the method described in this paper (23) . DISCUSSION The method presented is simple and effective for the detection of pregnane-3a,17a,20-triol and pregnane-3a,,17a,20a-triol-1 1-one in urine, and can be carried out routinely by a technician. No elaborate precautions are required and, in particular, purification of filter paper is not necessary. In tests of the urine of patients with adrenal hyperplasia or adrenal tumors, a single chromatogram is usually sufficient to show the presence and indicate the levels of these steroids. In some cases where there is uncertainty, a second chromatographic separation is required. The minimum amounts detectable are about 100 ,ug. per 24 hours for pregnanetriol and 50 j.g. per 24 hours for pregnanetriolone. The lower levels of pregnanetriol associated with normal adults and especially with normal children sometimes may not be detectable. The tests may be made more sensitive, or larger amounts of urine may be extracted; however, the method as presented is designed primarily to detect abnormally high levels.
The methods which have been in use for estimation of pregnanetriol (10, 12) and pregnanetriolone (15) are not specific for these steroids and demand their prior separation from related or interfering substances. Thus, estimation by means of acetaldehyde produced on periodate oxidation (10) is a general reaction for C21 steroids of the 17,20-dihydroxy-20-methyl series. Substances, in addition to pregnanetriol or pregnanetriolone, giving this reaction have been extracted from urine (6, 8) . The method -for pregnanetriol based on chromogens produced on reaction with concentrated sulfuric acid (12) requires adequate purification of extracts due to the poor specificity of the reagent. Pregnanetriolone produces an intensely fluorescent compound on heating with concentrated phosphoric acid, but fluorogenic substances other than this compound in neutral urine extracts are excreted by normal people and in increased amounts by patients with adrenal tumors and in late pregnancy (14, 17) .
Recently, De Courcy (24) elaborated a method for the estimation of pregnane-3a,17a,20-triols, and Finkelstein and Goldberg (16, 17) for pregnane-3a,17a,20a-triol-11-one. Both methods utilize paper chromatography for the separation of the respective compounds, which are detected by means of fluorescence. It is worth mentioning, however, that in the method of De Courcy only pregnanetriol, but not pregnanetriolone, is visualized by the reagent employed. On the other hand, in the method of Finkelstein and Goldberg, pregnanetriol is destroyed by the hot acid hydrolysis as used for the liberation of pregnanetriolone from its conjugate (25) .
Since pregnanetriol produces fluorescence and can be easily detected on paper with the 70 per cent phosphoric acid reagent used for estimation of pregnanetriolone, substitution of the hot acid treatment by enzymic hydrolysis, which liberates both compounds without destroying them, allows for their simultaneous estimation. Moreover, in enzymic hydrolysis, less chloroform extractable impurities are formed than in hot acid hydrolysis, thus making unnecessary the rigorous purification of the extracts described previously for the detection of pregnanetriolone (17) . The present method described primarily for clinical use, and obviating the use of precise optical apparatus such as spectrophotometer or fluorimeter, is semiquantitative. Used in conjunction with estimation of acetaldehydogenic (10) or fluorogenic substances (14) , it can give precise quantitative measurements of individual compounds such as pregnanetriol or pregnanetriolone and may be used to detect unknown steroids on the chromatograms. Results of such studies will be published elsewhere.
The differentiation between adrenal hyperplasia and adrenal tumor is a problem of clinical importance. Jailer, Gold, and Wallace (26) (28) and Thorn (29) ]. Bongiovanni (22) associated high excretion of the pregnanetriol-like fraction with adrenal hyperplasia and observed that on cortisone administration this fraction decreased. In addition to the original isolation of pregnanetriol from the urine of patients with the adreno-genital syndrome by Butler and Marrian  (1-3) , it has also been isolated from the urine of patients with adrenal tumors (4) , and from the urine of normal men (6) . High levels of pregnanetriol appear to be associated with adrenal tumors as well as with adrenal hyperplasia, and thus do not allow for differentiation between these two conditions. As to the decrease of pregnanetriol on cortisone treatment, it remains to be proved that such a decrease is more consistent than the corresponding decrease of the 17-ketosteroids. On the other hand, the consistent presence of pregnanetriolone in the urine of patients with adrenal hyperplasia and its apparent absence in detectable amounts from the urine of three patients with adrenal tumor can make it a valuable differential diagnostic aid between these conditions. It has been reported that one patient with the hypertensive form of adrenal hyperplasia (13, 30) excreted no detectable amounts of expected 11-oxy steroids in the urine; although pregnanetriolone was not specifically searched for in this work, it is desirable that data be obtained on the excretion of this steroid by such patients. It is fully realized that a general conclusion on the absence of pregnanetriolone from urine of patients with adrenal tumors is not permissible on the basis of the results obtained on only three cases of tumors examined so far. However, in view of the rarity of this disease and thus of a small chance that our laboratories (located in countries with relatively small populations) will be able to compile a large series of adrenal tumors within a reasonable time, it seems to us that by reporting on the difference in steroid excretion by patients with adrenal hyperplasia and adrenal tumors, research on larger series may be stimulated.
It was suggested in a previous paper (17) that pregnanetriolone is characteristic of adrenal hyper-plasia. Only six cases of adrenal hyperplasia were investigated. The presence of pregnanetriolone in an additional six patients with adrenal hyperplasia not receiving cortisone therapy and in six patients maintained on cortisone, reported in the present paper, greatly substantiates this supposition. On the other hand, analysis of urine of 24 "normal" people described here, of 37 reported previously (17) , and of an additional 25 "normal" persons (31) shows that pregnanetriolone is not detectable in "normal" persons' urine, and if present, it must be in relatively small quantities (less than 50 jug. per 24 hours). High levels are associated with adrenal hyperplasia (see Table I ). Children with adrenal hyperplasia of the virilizing type show definite presence of pregnanetriolone, and milligram quantities are excreted by adults with the adreno-genital syndrome due to adrenal hyperplasia.
SUMMARY
A method for the detection and estimation of urinary pregnane-3a,17a,20a-triol and pregnane3a,17a,20a-triol-11-one suitable for routine clinical use is described.
The results of estimation of the excretion of these steroids by 41 people, including "normal" persons and patients with adrenocortical hyperplasia or tumors of adrenal origin, are presented. Normally, pregnanetriolone is not excreted in detectable amounts but this steroid appears in relatively large amounts in the urine of patients with adrenocortical hyperplasia; pregnanetriolone has not been found in the urine of three patients with tumors of adrenal origin. On the other hand, high pregnanetriol levels appear to be associated with both adrenocortical hyperplasia and with tumors of adrenal origin.
The characteristic finding of pregnanetriolone in cases of adrenocortical hyperplasia should be a useful diagnostic aid.
